Comparison of the effect of continuous intravenous infusion of sodium valproate and midazolam on management of status epilepticus in children - 25/11/21
, Jamshid Yazdani Charati b, Salar Behzadnia cBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background and Objectives |
Status epilepticus as a pediatric emergency requires rapid seizure control in order to prevent subsequent disabilities. Therefore, the present study was conducted to compare the efficacy and side effects of continuous intravenous infusion of sodium valproate versus midazolam as a third-line treatment of status epilepticus in children.
Methodology |
This randomized clinical trial study included all children with convulsive and non-convulsive status epilepticus admitted to the pediatric intensive care unit (PICU) of the Bu-Ali Sina Hospital in Sari City (Mazandaran Province, Iran) who had not responded to first-line treatment with diazepam and second-line treatment with phenytoin or phenobarbital. They were consequently treated with continuous intravenous infusion of sodium valproate or midazolam to control persistent seizures.
Results |
The study comprised 70 patients who were randomly assigned to two equal groups of sodium valproate or midazolam treatment. The mean age of patients in group A (sodium valproate) and group B (midazolam) was 3.97 ± 3.33 and 3.84 ± 2.93 years, respectively. In the present study, the most common etiology of status epilepticus was remote symptomatic, accounting for 35% of cases in the two groups. Sodium valproate was effective in controlling status epilepticus in 91.4% of patients, while midazolam was found to be effective in 85.7% of patients (p > 0.05). Patients who received sodium valproate had shorter seizure duration after administration of the drug compared to those who received midazolam (p = 0.01). Eight patients in the midazolam group and two patients in the sodium valproate group were intubated (p = 0.023). The mean duration of stay in the PICU was 3.2 ± 1.4 and 5.6 ± 2.8 days in groups A and B, respectively, showing a significant difference (p = 0.001).
Conclusion |
According to our findings, intravenous infusion of sodium valproate can be used as an effective and relatively safe treatment in children with all types of status epilepticus, especially in challenging situations such as lack of intensive care units or respiratory problems.
Le texte complet de cet article est disponible en PDF.Keywords : Status epilepticus, Intravenous infusion of midazolam, Intravenous infusion of sodium valproate, Children
Plan
Vol 28 - N° 8
P. 696-701 - novembre 2021 Retour au numéro
Article précédent
- Medical check-up of newly arrived unaccompanied minors: A dedicated pediatric consultation service in a hospital
- A. Bergevin, M. Husain, M. Cruz, C. Le Blanc, A. Dieme, M.-L. Girardin, C. Toujouse, R. Ben Tkhayat, S. Slabab, O. Corseri, M. Maglorius, C. Vercamer, E. Eskander, E. Desselas, N. Lachaume, A. Garraffo, F. Sorge, E. Le Roux, J. Gaschignard, M. Caseris, A. Faye
- Frequency and status of depression and anxiety in mothers of children with inborn errors of metabolism with restricted diet, with and without risk of metabolic crises
- Pelin Teke Kisa, Ozlem Unal Uzun, Mehmet Gunduz, Fatma Selda Bulbul, Engin Kose, Nur Arslan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?